15.87 USD
+0.24 (+1.54%)
15.5 USD
-0.37 (-2.33%)
Overall SGRY gets a fundamental rating of 3 out of 10. We evaluated SGRY against 101 industry peers in the Health Care Providers & Services industry. SGRY has a medium profitability rating, but doesn't score so well on its financial health evaluation. SGRY has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
SGRY had positive earnings in the past year.
In the past year SGRY had a positive cash flow from operations.
SGRY had negative earnings in each of the past 5 years.
Each year in the past 5 years SGRY had a positive operating cash flow.
1.2 Ratios
The Return On Assets of SGRY (-2.16%) is comparable to the rest of the industry.
SGRY has a Return On Equity (-9.94%) which is in line with its industry peers.
With a Return On Invested Capital value of 5.57%, SGRY perfoms like the industry average, outperforming 57.84% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 9.58%.
The last Return On Invested Capital (5.57%) for SGRY is above the 3 year average (5.03%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROIC | 5.57% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
SGRY's Operating Margin of 15.78% is amongst the best of the industry. SGRY outperforms 92.16% of its industry peers.
SGRY's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 26.57%, SGRY perfoms like the industry average, outperforming 54.90% of the companies in the same industry.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SGRY has more shares outstanding
SGRY has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SGRY is higher compared to a year ago.
2.2 Solvency
SGRY has an Altman-Z score of 0.76. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.76, SGRY is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
SGRY has a debt to FCF ratio of 18.37. This is a negative value and a sign of low solvency as SGRY would need 18.37 years to pay back of all of its debts.
With a Debt to FCF ratio value of 18.37, SGRY perfoms like the industry average, outperforming 41.18% of the companies in the same industry.
A Debt/Equity ratio of 2.00 is on the high side and indicates that SGRY has dependencies on debt financing.
With a Debt to Equity ratio value of 2.00, SGRY is not doing good in the industry: 73.53% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Altman-Z | 0.76 |
ROIC/WACC0.63
WACC8.88%
2.3 Liquidity
A Current Ratio of 1.88 indicates that SGRY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.88, SGRY is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
A Quick Ratio of 1.72 indicates that SGRY should not have too much problems paying its short term obligations.
The Quick ratio of SGRY (1.72) is better than 71.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
The Revenue has grown by 10.14% in the past year. This is quite good.
SGRY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.20% yearly.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
The Earnings Per Share is expected to grow by 12.89% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.88% on average over the next years.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.35, the valuation of SGRY can be described as rather expensive.
SGRY's Price/Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 71.57% of the companies in the same industry.
When comparing the Price/Earnings ratio of SGRY to the average of the S&P500 Index (26.92), we can say SGRY is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 21.17, the valuation of SGRY can be described as rather expensive.
SGRY's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.46. SGRY is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.35 | ||
| Fwd PE | 21.17 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SGRY is valued a bit cheaper than the industry average as 78.43% of the companies are valued more expensively.
84.31% of the companies in the same industry are more expensive than SGRY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.58 | ||
| EV/EBITDA | 8.4 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
5. Dividend
5.1 Amount
SGRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.87
+0.24 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners80.74%
Inst Owner Change5.61%
Ins Owners1.11%
Ins Owner Change-0.17%
Market Cap2.05B
Revenue(TTM)3.29B
Net Income(TTM)-171.90M
Analysts81.11
Price Target26.52 (67.11%)
Short Float %18.31%
Short Ratio7.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-8.13%
PT rev (3m)-16.67%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)-34.77%
EPS NY rev (1m)-24.86%
EPS NY rev (3m)-25.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.75%
Revenue NY rev (1m)-1.84%
Revenue NY rev (3m)-1.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.35 | ||
| Fwd PE | 21.17 | ||
| P/S | 0.62 | ||
| P/FCF | 10.58 | ||
| P/OCF | 7.28 | ||
| P/B | 1.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.4 |
EPS(TTM)0.78
EY4.91%
EPS(NY)0.75
Fwd EY4.72%
FCF(TTM)1.5
FCFY9.45%
OCF(TTM)2.18
OCFY13.73%
SpS25.42
BVpS13.37
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROCE | 7.05% | ||
| ROIC | 5.57% | ||
| ROICexc | 5.57% | ||
| ROICexgc | 18.41% | ||
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% | ||
| FCFM | 5.9% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Debt/EBITDA | 5.17 | ||
| Cap/Depr | 58.56% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | 0.76 |
F-Score4
WACC8.88%
ROIC/WACC0.63
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y15.88%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y18.25%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
Can you provide the valuation status for SURGERY PARTNERS INC?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for SGRY stock?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 20.35 and the Price/Book (PB) ratio is 1.19.
Is the dividend of SURGERY PARTNERS INC sustainable?
The dividend rating of SURGERY PARTNERS INC (SGRY) is 0 / 10 and the dividend payout ratio is 0%.